公开(公告)号：EP3845533A1

公开(公告)日：2021-07-07

申请号：EP19854536.0

申请日：2019-08-26

申请人： Sumitomo Dainippon Pharma Co., Ltd.

发明人： KAMIOKA, Seiji ,  BAN, Hitoshi ,  SHIMADA, Naoaki ,  HIROSE, Wataru ,  ARAKAWA, Akihiko ,  YAMAZAKI, Kazuto ,  HIRA, Kenjiro

IPC分类号： C07D471/10 ,  A61K31/506 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07D487/10

摘要： The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R 1 - R 4 are hydrogen atom or the like, and a - d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

公开(公告)号：EP3835304A1

公开(公告)日：2021-06-16

申请号：EP19846598.1

申请日：2019-08-07

申请人： Sumitomo Dainippon Pharma Co., Ltd.

发明人： KAMIOKA, Seiji ,  SHIMADA, Naoaki ,  BAN, Hitoshi ,  YAMAZAKI, Kazuto ,  ARAKAWA, Akihiko ,  HIROSE, Wataru

IPC分类号： C07D519/00 ,  A61K31/439 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07D495/04

摘要： The present invention relates to the compound of formula (1a) wherein a - d and p are 1 or 2, R 1 - R 4 are hydrogen atom or the like, and R 18 is -CF 3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.